These immune check points Programmed death-ligand 1 (PDL-1), B7-H3 (CD276), and B7-H6 (NCR3LG1) have been associated with aggressiveness and poor prognosis in glioma patients (31–33). This evidence concerns the gene NCR3LG1 and central nervous system cancer.